Market Commentary and Intraday News
On the Call: Amgen CEO Robert Bradway
328 days ago
By The Associated Press
During a conference call with analysts about Amgen Inc.'s second-quarter results, CEO Robert Bradway was asked about the biotech company's top-selling drug, Enbrel for rheumatoid arthritis, severe psoriasis and other immune disorders. It's been on the market for 14 years and brings in about $4 billion a year, about one-quarter of Amgen's revenue.
QUESTION: What can you say about potential candidates to eventually replace Enbrel?
ANSWER: The bar established by Enbrel is a high one, and we have found it difficult to find molecules that offer superior safety and efficacy (but continue to look).
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.